Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $1.5 billion.

  • Northwest Biotherapeutics' Shares Outstanding (Weighted Average) rose 18.76% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 18.76%. This contributed to the annual value of $1.3 billion for FY2024, which is 12.45% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $1.5 billion for Q3 2025, which was up 3.11% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Shares Outstanding (Weighted Average) peaked at $1.5 billion during Q3 2025, and registered a low of $842.1 million during Q1 2021.
  • For the 3-year period, Northwest Biotherapeutics' Shares Outstanding (Weighted Average) averaged around $1.2 billion, with its median value being $1.2 billion (2024).
  • Data for Northwest Biotherapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 29.82% (in 2021) over the last 5 years.
  • Northwest Biotherapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $927.8 million in 2021, then increased by 13.48% to $1.1 billion in 2022, then rose by 9.59% to $1.2 billion in 2023, then increased by 12.45% to $1.3 billion in 2024, then increased by 18.76% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.4 billion during Q1 2025.